HR Execs on the Move

IMIDomics

www.imidomics.com

 
IMIDomics is a biotechnology company focused on Patient-Centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d`Hebron Institute of Research, to establish a deeper understanding of IMID diseases. By doing so, IMIDomics has identified previously unrecognized targets, six of which have been selected for development. By relying on access ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Fytokem Products

Fytokem Products Inc. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Incept BioSystems

Incept BioSystems is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Elevian

Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.

Newlight Technologies

Newlight Technologies is a company based in Irvine, California known for carbon sequestration into plastics.

Arkuda Therapeutics

Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.